# BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

> **NCT04454528** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 27 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** Pembrolizumab infusion
- **PROCEDURE:** Blood and tissue sampling

## Key facts

- **NCT ID:** NCT04454528
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-07
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04454528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04454528, "BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04454528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*